Literature DB >> 3174494

Nonrandom involvement of chromosome 4 in the progression of rat prostatic cancer.

J T Isaacs1, B Hukku.   

Abstract

Owing to progression of the original spontaneous Dunning R-3327 rat prostatic cancer, a large series of transplantable prostatic tumors have been isolated that differ widely in their histological degree of differentiation, growth rate, androgen sensitivity, and metastatic ability. Using these parameters as criteria, the full spectrum of disease progression is represented within this Dunning system of rat prostatic cancers, ranging from slow-growing, well-differentiated, androgen-sensitive, nonmetastatic forms to fast-growing, anaplastic, androgen-independent, highly metastatic forms. Cytogenetic analysis of the two least progressionally advanced Dunning cancers (i.e., histologically well-differentiated, slow-growing, nonmetastatic variants) demonstrated no structural or numerical chromosomal aberration, suggesting that the initial development of prostatic cancer may not require detectable cytogenetic changes. In contrast, all 16 of the progressionally more advanced Dunning variants analyzed had a series of characteristic structural and/or numerical chromosomal aberrations that minimally involved chromosome 4. This nonrandom involvement of chromosome 4 was consistently observed regardless of whether the karyotype of the cancer was near-diploid or hyperaneuploid, suggesting that chromosome 4 aberrations are specifically involved in the progression of rat prostatic cancer. In addition, all four variants that were highly metastatic had, besides aberration of chromosome 4, structural aberrations involving chromosomes 1, 2, and 11. Of the 14 variants that did not have a high metastatic ability, only two had a similar aberrations involving chromosomes 1, 2, 4, and 11, suggesting that these specific chromosomal aberrations may be necessary, albeit not sufficient, for a high metastatic ability of rat prostatic cancers.

Entities:  

Mesh:

Year:  1988        PMID: 3174494     DOI: 10.1002/pros.2990130208

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  6 in total

1.  HiSStology: high spectral and spatial resolution magnetic resonance imaging detection of vasculature validated by histology and micro-computed tomography.

Authors:  Chad R Haney; Charles A Pelizzari; Sean Foxley; Marta A Zamora; Devkumar Mustafi; Maria Tretiakova; Shihong Li; Xiaobing Fan; Gregory S Karczmar
Journal:  Mol Imaging       Date:  2011-03-01       Impact factor: 4.488

Review 2.  Molecular and cellular markers for metastatic prostate cancer.

Authors:  C W Rinker-Schaeffer; W B Isaacs; J T Isaacs
Journal:  Cancer Metastasis Rev       Date:  1993-03       Impact factor: 9.264

Review 3.  Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: biological significance and clinical implications.

Authors:  L A Giroldi; J A Schalken
Journal:  Cancer Metastasis Rev       Date:  1993-03       Impact factor: 9.264

Review 4.  Prostate cancer--biology of metastasis and its clinical implications.

Authors:  J T Dong; C W Rinker-Schaeffer; T Ichikawa; J C Barrett; J T Isaacs
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

5.  The in vitro effect of electromagnetically generated shock waves (Lithostar) on the Dunning R3327 PAT-2 rat prostatic cancer cell-line. A potentiating effect on the in vitro cytotoxicity of vinblastin.

Authors:  G O Oosterhof; G A Smits; J E de Ruyter; R J van Moorselaar; J A Schalken; F M Debruyne
Journal:  Urol Res       Date:  1989

6.  IL-15 regulates migration, invasion, angiogenesis and genes associated with lipid metabolism and inflammation in prostate cancer.

Authors:  Krizia Rohena-Rivera; María M Sánchez-Vázquez; Diana A Aponte-Colón; Ingrid S Forestier-Román; Mario E Quintero-Aguiló; Magaly Martínez-Ferrer
Journal:  PLoS One       Date:  2017-04-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.